MedTrace Logo

A Clinical Trial of a Recombinant Adenovirus 5 Vectored COVID-19 Vaccine (Ad5-nCoV) With Two Doses in Healthy Adults

NCT04552366 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 149

Last updated 2023-05-24

No results posted yet for this study

Summary

This is a clinical trial to evaluate the safety and immunogenicity of a recombinant adenovirus 5 vectored COVID-19 vaccine (Ad5-nCoV) with two doses and with different adminstration routes in healthy adults aged 18 years and older.

Conditions

Interventions

BIOLOGICAL

Ad5-nCoV

Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector)

Sponsors & Collaborators

  • Zhongnan Hospital

    collaborator OTHER

  • Institute of Biotechnology, Academy of Military Medical Sciences, PLA of China

    lead OTHER

Study Design

Allocation
NON_RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2020-09-29
Primary Completion
2020-12-31
Completion
2021-04-30

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04552366 on ClinicalTrials.gov